Lv1
60 积分 2023-08-03 加入
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
15天前
已完结
Managing side effects of JAK inhibitors for myelofibrosis in clinical practice
1个月前
已完结
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study
1个月前
已完结
Emerging Therapeutic Approaches for Anemia in Myelofibrosis
3个月前
已完结
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study
4个月前
已完结
Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future
7个月前
已完结
Baseline Erythropoietin Level Predicts Luspatercept Response in Chinese Patients with Myelodysplastic Syndrome: A Propensity Score-Matched Analysis
8个月前
已完结
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
8个月前
已完结
MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial
8个月前
已关闭
Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study
8个月前
已关闭
皖公网安备34019202002308
